Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study

In a study of data from the United Kingdom's primary care database, THIN, Joseph Hayes and colleagues report on adverse events associated with use of lithium and other maintenance treatments for bipolar disorder.

Vyšlo v časopise: Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study. PLoS Med 13(8): e32767. doi:10.1371/journal.pmed.1002058
Kategorie: Research Article
prolekare.web.journal.doi_sk: 10.1371/journal.pmed.1002058


In a study of data from the United Kingdom's primary care database, THIN, Joseph Hayes and colleagues report on adverse events associated with use of lithium and other maintenance treatments for bipolar disorder.


1. Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382(9904):1575–86. doi: 10.1016/S0140-6736(13)61611-6 23993280

2. Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet. 2016; 387(10027):1561–72. doi: 10.1016/S0140-6736(15)00241-X

3. National Institute for Health and Care Excellence. Bipolar Disorder: the Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary Care. GC185. London, UK: NICE; 2014

4. Severus E, Taylor MJ, Sauer C, Pfennig A, Ritter P, Bauer M, et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int J Bipolar Disord. 2014;2(1):15.

5. Miura T, Noma H, Furukawa TA, Mitsuyasu H, Tanaka S, Stockton S, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2014;1(5):351–9.

6. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(4 Suppl):1–50.

7. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar disord. 2013;15(1):1–44. doi: 10.1111/bdi.12025 23237061

8. National Institute for Health and Care Excellence. Bipolar Disorder: the Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary Care. GC38. London, UK: NICE; 2006.

9. Hayes J, Prah P, Nazareth I, King M, Walters K, Petersen I, et al. Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995–2009. PLoS ONE. 2011;6(12):e28725. doi: 10.1371/journal.pone.0028725 22163329

10. Bech P. The full story of lithium. Psychother Psychosom. 2006;75(5):265–9. 16899962

11. McKnight R, Adida M, Budge K, Stockton S, Goodwin G, Geddes J. Lithium toxicity profile: a systematic review and meta-analysis. Lancet. 2012;379(9817):721–728. doi: 10.1016/S0140-6736(11)61516-X 22265699

12. Close H, Reilly J, Mason JM, et al. Renal failure in lithium-treated bipolar disorder: a retrospective cohort study. PLoS ONE. 2014;9(3):e90169. doi: 10.1371/journal.pone.0090169 24670976

13. Shine B, McKnight RF, Leaver L, Geddes JR. Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet. 2015; 386(992):461–468.

14. Kessing LV, Gerds TA, Feldt-Rasmussen B, Andersen PK, Licht RW. Use of Lithium and Anticonvulsants and the Rate of Chronic Kidney Disease: A Nationwide Population-Based Study. JAMA Psychiatry. 2015; 72(12):1182–91.

15. Murru A, Popovic D, Pacchiarotti I, Hidalgo D, León-Caballero J, Vieta E. Management of Adverse Effects of Mood Stabilizers. Curr Psychiatry Rep. 2015 Aug 1;17(8):603.

16. Tarricone I, Ferrari Gozzi B, Serretti A, Grieco D, Berardi D. Weight gain in antipsychotic-naive patients: a review and meta-analysis. Psychol Med. 2010;40(02):187–200.

17. Haupt DW. Differential metabolic effects of antipsychotic treatments. Eur Neuropsychopharmacol. 2006;16:S149–S55. 16872808

18. Dols A, Sienaert P, van Gerven H, Schouws S, Stevens A, Kupka R, Stek ML. The prevalence and management of side effects of lithium and anticonvulsants as mood stabilizers in bipolar disorder from a clinical perspective: a review. Int Clin Psychopharmacol. 2013; 1;28(6):287–96. doi: 10.1097/YIC.0b013e32836435e2 23873292

19. Ozcanli T, Erdogan A, Ozdemir S, Onen B, Ozmen M, Doksat K, Sonsuz A. Severe liver enzyme elevations after three years of olanzapine treatment: a case report and review of olanzapine associated hepatotoxicity. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2006;30(6):1163–6. 16632162

20. Atasoy N, Erdogan A, Yalug I, Ozturk U, Konuk N, Atik L, Ustundag Y. A review of liver function tests during treatment with atypical antipsychotic drugs: a chart review study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(6):1255–60. 17600607

21. El Hajj I, Sharara AI, Rockey DC. Subfulminant liver failure associated with quetiapine. Eur J Gastroenterol Hepatol. 2004;16(12):1415–8.

22. IMS Health. Accessed October 28 2015.

23. Blak B, Thompson M, Bourke A, editors. National representativeness and data quality of the Health Improvement Network (THIN) database of primary care information for epidemiological research. 9th Annual Conference of the UK Federation of Primary Care Research Organisations Podium presentation Liverpool, UK; 2006.

24. Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care. 2011;19(4):251–5. 22828580

25. Lis Y, Mann RD. The VAMP Research multi-purpose database in the UK. J Clin Epidemiol. 1995;48(3):431–43. 7897464

26. Hardoon S, Hayes JF, Blackburn R, et al. Recording of severe mental illness in United Kingdom primary care, 2000–2010. PLoS ONE. 2013; 8(12): e82365.

27. Nazareth I, King M, Haines A, Rangel L, Myers S. Accuracy of diagnosis of psychosis on general practice computer system. BMJ. 1993;307(6895):32–4. 8343670

28. Chisholm J. The Read clinical classification. BMJ. 1990;300(6732):1092. 2344534

29. Davé S, Petersen I. Creating medical and drug code lists to identify cases in primary care databases. Pharmacoepidemiol Drug Saf. 2009;18(8):704–7. doi: 10.1002/pds.1770 19455565

30. Health and Social Care Information Centre. Prescriptions Dispensed in the Community, Statistics for England—2001–2011. 2012. Health and Social Care Information Centre, UK.

31. Horsfall L, Walters K, Petersen I. Identifying periods of acceptable computer usage in primary care research databases. Pharmacoepidemiol Drug Saf. 2013;22(1):64–9. doi: 10.1002/pds.3368 23124958

32. Maguire A, Blak BT, Thompson M. The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiol Drug Saf. 2009;18(1):76–83. doi: 10.1002/pds.1688 19065600

33. Beastall G, Beckett G, Franklyn J, et al. UK Guidelines for the use of thyroid function tests. The association for Clinical Biochemistry. 2006.

34. Vassalotti JA, Stevens LA, Levey AS. Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis. 2007;50(2):169–80. 17660017

35. Crowe E, Halpin D, Stevens P. Guidelines: early identification and management of chronic kidney disease: summary of NICE guidance. BMJ. 2008;337:a1530

36. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604–12. 19414839

37. Smellie WSA, Vanderpump M, Fraser WD, Bowley R, Shaw N. Best practice in primary care pathology: review 11. J Clin Pathol. 2008;61(4):410–8. 17965216

38. Manu P, Dima L, Shulman M, Vancampfort D, De Hert M, Correll C. Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psych Scand. 2015;132(2):97–108.

39. John W. Use of HbA1c in the diagnosis of diabetes mellitus in the UK. The implementation of World Health Organization guidance 2011. Diabet Med. 2012;29(11):1350–7. doi: 10.1111/j.1464-5491.2012.03762.x 22957983

40. Sabin CA. Pitfalls of assessing hepatotoxicity in trials and observational cohorts. Clin Infect Dis. 2004;38(Supplement 2):S56–64.

41. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79(387):516–24.

42. Holmes WM. Using propensity scores in quasi-experimental designs. Thousand Oaks, California, US; SAGE Publications: 2013.

43. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41–55.

44. Mathur R, Bhaskaran K, Chaturvedi N, Leon DA, Grundy E, Smeeth L. Completeness and usability of ethnicity data in UK-based primary care and hospital databases. J Public Health. 2014;36(4):684–92.

45. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999;150(4):327–33. 10453808

46. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424. 21818162

47. Seeger JD, Kurth T, Walker AM. Use of propensity score technique to account for exposure-related covariates: an example and lesson. Med Care. 2007;45(10):S143–S8. 17909373

48. Stuart EA. Matching methods for causal inference: A review and a look forward. Stat Sci. 2010;25(1):1. 20871802

49. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69(1):239–41.

50. d’Agostino RB. Tutorial in biostatistics: propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265–81.

51. Lin TH, Dayton CM. Model selection information criteria for non-nested latent class models. J Educ Behav Stat. 1997;22(3):249–64.

52. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509.

53. Noordzij M, Leffondré K, van Stralen KJ, Zoccali C, Dekker FW, Jager KJ. When do we need competing risks methods for survival analysis in nephrology? Nephrol Dial Transplant. 2013;28(11):2670–7. doi: 10.1093/ndt/gft355 23975843

54. Seaman SR, White IR. Review of inverse probability weighting for dealing with missing data. Stat Methods Med Res. 2013;22(3):278–95. doi: 10.1177/0962280210395740 21220355

55. StataCorp. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP: 2015.

56. Aiff H, Attman PO, Aurell M, Bendz H, Schön S, Svedlund J. End-stage renal disease associated with prophylactic lithium treatment. Eur Neuropsychopharmacol. 2014;24(4):540–4. doi: 10.1016/j.euroneuro.2014.01.002 24503277

57. Clos S, Rauchhaus P, Severn A, Cochrane L, Donnan PT. Long-term effect of lithium maintenance therapy on estimated glomerular filtration rate in patients with affective disorders: a population-based cohort study. Lancet Psychiatry. 2015;2(12):1075–83. doi: 10.1016/S2215-0366(15)00316-8 26453408

58. Kibirige D, Luzinda K, Ssekitoleko R. Spectrum of lithium induced thyroid abnormalities: a current perspective. Thyroid Res. 2013;6(1):3. doi: 10.1186/1756-6614-6-3 23391071

59. Lazarus JH. Lithium and thyroid. Best Prac Res Clin Endocrinol Metab. 2009;23(6):723–33.

60. Fagiolini A, Kupfer DJ, Scott J, Swartz HA, Cook D, Novick DM, et al. Hypothyroidism in patients with bipolar I disorder treated primarily with lithium. Epidemiol Psichiatr Soc. 2006;15(02):123–7.

61. Souza FG, Mander AJ, Foggo M, Dick H, Shearing CH, Goodwin GM. The effects of lithium discontinuation and the non-effect of oral inositol upon thyroid hormones and cortisol in patients with bipolar affective disorder. J Affect Disord. 1991; 22(3):165–70. 1918659

62. Khandwala HM, Uum SV. Reversible hypercalcemia and hyperparathyroidism associated with lithium therapy: case report and review of literature. Endocr Prac. 2006;12(1):54–8.

63. Lehmann SW, Lee J. Lithium-associated hypercalcemia and hyperparathyroidism in the elderly: What do we know? J Affect Disord. 2013;146(2):151–7. doi: 10.1016/j.jad.2012.08.028 22985484

64. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects. CNS Drugs. 2005;19(1):1–93.

65. Nashed MG, Restivo MR, Taylor VH. Olanzapine-induced weight gain in patients with bipolar I disorder: a meta-analysis. Prim Care Companion CNS Disord. 2011;13(6). doi: 10.4088/PCC.11r01174

66. Austin PC, Mamdani MM, Stukel TA, Anderson GM, Tu JV. The use of the propensity score for estimating treatment effects: administrative versus clinical data. Stat Med. 2005;24(10):1563–78. 15706581

67. Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, Vermeulen MJ. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA. 2007;297(3):278–85. 17227979

68. Cipriani A, Hawton K, Stockton S, Geddes J. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:f3646. doi: 10.1136/bmj.f3646 23814104

Interné lekárstvo

Článok vyšiel v časopise

PLOS Medicine

2016 Číslo 8
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle

Zvýšte si kvalifikáciu online z pohodlia domova

Hereditární TTR amyloidóza – vzácné, nebo jen neodhalené onemocnění? 2. díl
nový kurz

Eozinofilní granulomatóza s polyangiitidou

Betablokátory a Ca antagonisté z jiného úhlu
Autori: prof. MUDr. Michal Vrablík, Ph.D., MUDr. Petr Janský

Autori: doc. MUDr. Petr Čáp, Ph.D.

Farmakoterapie akutní a chronické bolesti

Všetky kurzy
Zabudnuté heslo

Nemáte účet?  Registrujte sa

Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.


Nemáte účet?  Registrujte sa